Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SPINK1

SPINK1

Basics

Aliases:
This biomarker is also known as:
  • Serine Protease Inhibitor, Kazal-Type 1,
  • Pancreatic Secretory Trypsin Inhibitor,
  • Spink3,
  • TCP,
  • Tumor-Associated Trypsin Inhibitor,
  • Serine Protease Inhibitor, Kazal Type 1,
  • PCTT,
  • Serine Peptidase Inhibitor, Kazal Type 1,
  • PSTI,
  • TATI,

View in BioMuta

Description…

SPINK1 is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. Its physiological function is to prevent the trypsin-catalyzed premature activation of zymogens within the pancreas. Mutations in SPINK1 are associated with hereditary pancreatitis and tropical calcific pancreatitis.

Attributes

QA State: Curated
Type: Gene
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Two
QA State: Curated

Overview

High levels of SPINK1 have been associated with a greater rate of prostate cancer recurrence.

Performance Comment

Increased SPINK1 transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html